annual accounts payable:
$10.25M-$1.57M(-13.26%)Summary
- As of today (June 22, 2025), HALO annual accounts payable is $10.25 million, with the most recent change of -$1.57 million (-13.26%) on December 31, 2024.
- During the last 3 years, HALO annual accounts payable has risen by +$8.71 million (+565.09%).
- HALO annual accounts payable is now -42.07% below its all-time high of $17.69 million, reached on December 31, 2022.
Performance
HALO Accounts payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly accounts payable:
$20.07M+$9.82M(+95.86%)Summary
- As of today (June 22, 2025), HALO quarterly accounts payable is $20.07 million, with the most recent change of +$9.82 million (+95.86%) on March 31, 2025.
- Over the past year, HALO quarterly accounts payable has increased by +$6.75 million (+50.65%).
- HALO quarterly accounts payable is now at all-time high.
Performance
HALO quarterly accounts payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Accounts payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
HALO Accounts payable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -13.3% | +50.6% |
| 3 y3 years | +565.1% | +1485.6% |
| 5 y5 years | +59.3% | +141.3% |
HALO Accounts payable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -42.1% | +565.1% | at high | +1485.6% |
| 5 y | 5-year | -42.1% | +565.1% | at high | +4536.0% |
| alltime | all time | -42.1% | +642.7% | at high | >+9999.0% |
HALO Accounts payable History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $20.07M(+95.9%) |
| Dec 2024 | $10.25M(-13.3%) | $10.25M(-17.3%) |
| Sep 2024 | - | $12.40M(-19.7%) |
| Jun 2024 | - | $15.43M(+15.8%) |
| Mar 2024 | - | $13.32M(+12.8%) |
| Dec 2023 | $11.82M(-33.2%) | $11.82M(-38.8%) |
| Sep 2023 | - | $19.32M(+90.9%) |
| Jun 2023 | - | $10.12M(+16.4%) |
| Mar 2023 | - | $8.70M(-50.9%) |
| Dec 2022 | $17.69M(+1048.2%) | $17.69M(-2.6%) |
| Sep 2022 | - | $18.17M(+48.5%) |
| Jun 2022 | - | $12.23M(+866.2%) |
| Mar 2022 | - | $1.27M(-17.8%) |
| Dec 2021 | $1.54M(-20.1%) | $1.54M(-53.6%) |
| Sep 2021 | - | $3.32M(-27.2%) |
| Jun 2021 | - | $4.56M(+752.9%) |
| Mar 2021 | - | $535.00K(-72.3%) |
| Dec 2020 | $1.93M(-70.0%) | $1.93M(+345.3%) |
| Sep 2020 | - | $433.00K(-89.4%) |
| Jun 2020 | - | $4.07M(-51.1%) |
| Mar 2020 | - | $8.32M(+29.3%) |
| Dec 2019 | $6.43M(+57.7%) | $6.43M(+49.1%) |
| Sep 2019 | - | $4.31M(-65.4%) |
| Jun 2019 | - | $12.47M(+204.9%) |
| Mar 2019 | - | $4.09M(+0.2%) |
| Dec 2018 | $4.08M(-48.7%) | $4.08M(+22.5%) |
| Sep 2018 | - | $3.33M(-46.2%) |
| Jun 2018 | - | $6.19M(+70.5%) |
| Mar 2018 | - | $3.63M(-54.4%) |
| Dec 2017 | $7.95M(+122.1%) | $7.95M(+91.4%) |
| Sep 2017 | - | $4.15M(-26.5%) |
| Jun 2017 | - | $5.65M(+83.5%) |
| Mar 2017 | - | $3.08M(-13.9%) |
| Dec 2016 | $3.58M(-20.5%) | $3.58M(-22.9%) |
| Sep 2016 | - | $4.64M(+27.2%) |
| Jun 2016 | - | $3.65M(-41.2%) |
| Mar 2016 | - | $6.21M(+38.1%) |
| Dec 2015 | $4.50M(+49.8%) | $4.50M(+1.4%) |
| Sep 2015 | - | $4.44M(+7.2%) |
| Jun 2015 | - | $4.14M(+25.4%) |
| Mar 2015 | - | $3.30M(+9.9%) |
| Dec 2014 | $3.00M | $3.00M(-30.8%) |
| Sep 2014 | - | $4.34M(+11.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2014 | - | $3.91M(-54.8%) |
| Mar 2014 | - | $8.66M(+176.2%) |
| Dec 2013 | $3.13M(+38.0%) | $3.13M(-43.9%) |
| Sep 2013 | - | $5.59M(-25.3%) |
| Jun 2013 | - | $7.48M(+159.3%) |
| Mar 2013 | - | $2.88M(+27.0%) |
| Dec 2012 | $2.27M(-69.9%) | $2.27M(-35.6%) |
| Sep 2012 | - | $3.53M(+69.0%) |
| Jun 2012 | - | $2.09M(-30.7%) |
| Mar 2012 | - | $3.01M(-60.2%) |
| Dec 2011 | $7.56M(+97.8%) | $7.56M(+519.5%) |
| Sep 2011 | - | $1.22M(-29.6%) |
| Jun 2011 | - | $1.73M(+19.3%) |
| Mar 2011 | - | $1.45M(-62.0%) |
| Dec 2010 | $3.82M(+35.5%) | $3.82M(+109.0%) |
| Sep 2010 | - | $1.83M(-13.0%) |
| Jun 2010 | - | $2.10M(-50.6%) |
| Mar 2010 | - | $4.25M(+50.7%) |
| Dec 2009 | $2.82M(-57.7%) | $2.82M(-44.9%) |
| Sep 2009 | - | $5.12M(-5.7%) |
| Jun 2009 | - | $5.43M(+2.4%) |
| Mar 2009 | - | $5.30M(-20.5%) |
| Dec 2008 | $6.67M(+118.2%) | $6.67M(+61.0%) |
| Sep 2008 | - | $4.14M(+47.1%) |
| Jun 2008 | - | $2.81M(-17.2%) |
| Mar 2008 | - | $3.40M(+11.2%) |
| Dec 2007 | $3.06M(+51.5%) | $3.06M(+11.9%) |
| Sep 2007 | - | $2.73M(+76.3%) |
| Jun 2007 | - | $1.55M(+44.4%) |
| Mar 2007 | - | $1.07M(-46.9%) |
| Dec 2006 | $2.02M(+46.2%) | $2.02M(+41.3%) |
| Sep 2006 | - | $1.43M(+29.1%) |
| Jun 2006 | - | $1.11M(-31.8%) |
| Mar 2006 | - | $1.62M(+17.5%) |
| Dec 2005 | $1.38M(-7.2%) | $1.38M(-4.2%) |
| Sep 2005 | - | $1.44M(+1.9%) |
| Jun 2005 | - | $1.41M(-20.1%) |
| Mar 2005 | - | $1.77M(+18.9%) |
| Dec 2004 | $1.49M | $1.49M(-22.7%) |
| Sep 2004 | - | $1.92M(+61.4%) |
| Jun 2004 | - | $1.19M(+87.0%) |
| Mar 2004 | - | $637.30K(>+9900.0%) |
| Mar 2002 | - | $2900.00 |
FAQ
- What is Halozyme Therapeutics annual accounts payable?
- What is the all time high annual accounts payable for Halozyme Therapeutics?
- What is Halozyme Therapeutics annual accounts payable year-on-year change?
- What is Halozyme Therapeutics quarterly accounts payable?
- What is the all time high quarterly accounts payable for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly accounts payable year-on-year change?
What is Halozyme Therapeutics annual accounts payable?
The current annual accounts payable of HALO is $10.25M
What is the all time high annual accounts payable for Halozyme Therapeutics?
Halozyme Therapeutics all-time high annual accounts payable is $17.69M
What is Halozyme Therapeutics annual accounts payable year-on-year change?
Over the past year, HALO annual accounts payable has changed by -$1.57M (-13.26%)
What is Halozyme Therapeutics quarterly accounts payable?
The current quarterly accounts payable of HALO is $20.07M
What is the all time high quarterly accounts payable for Halozyme Therapeutics?
Halozyme Therapeutics all-time high quarterly accounts payable is $20.07M
What is Halozyme Therapeutics quarterly accounts payable year-on-year change?
Over the past year, HALO quarterly accounts payable has changed by +$6.75M (+50.65%)